196 related articles for article (PubMed ID: 37909894)
1. Bimekizumab for the treatment of psoriatic arthritis.
Tanaka Y; Shaw S
Expert Rev Clin Immunol; 2024 Feb; 20(2):155-168. PubMed ID: 37909894
[TBL] [Abstract][Full Text] [Related]
2. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
Ali Z; Matthews R; Al-Janabi A; Warren RB
Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
[TBL] [Abstract][Full Text] [Related]
3. Bimekizumab for the treatment of psoriatic disease.
Natsis NE; Gottlieb AB
Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
[TBL] [Abstract][Full Text] [Related]
4. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
5. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
[TBL] [Abstract][Full Text] [Related]
6. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.
Oliveira DG; Faria R; Torres T
Drug Des Devel Ther; 2021; 15():1045-1053. PubMed ID: 33727793
[TBL] [Abstract][Full Text] [Related]
7. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab: A Review in Psoriatic Arthritis.
Nie T; Shirley M
Drugs; 2024 May; ():. PubMed ID: 38703349
[TBL] [Abstract][Full Text] [Related]
9. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
[TBL] [Abstract][Full Text] [Related]
10. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden.
Sigurdardottir V; Engstrom A; Berling P; Olofsson T; Oldsberg L; Sadler S; Parra-Padilla D; Melis L; Willems D
J Med Econ; 2023; 26(1):1190-1200. PubMed ID: 37712618
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.
Ruggiero A; Potestio L; Martora F; Villani A; Comune R; Megna M
Expert Opin Drug Saf; 2023; 22(5):355-362. PubMed ID: 37222656
[TBL] [Abstract][Full Text] [Related]
14. Bimekizumab for psoriasis.
Rodrigues MA; Freitas E; Torres T
Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
[TBL] [Abstract][Full Text] [Related]
15. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Ritchlin CT; Kavanaugh A; Merola JF; Schett G; Scher JU; Warren RB; Gottlieb AB; Assudani D; Bedford-Rice K; Coarse J; Ink B; McInnes IB
Lancet; 2020 Feb; 395(10222):427-440. PubMed ID: 32035552
[TBL] [Abstract][Full Text] [Related]
16. Bimekizumab for the treatment of psoriasis.
Thapar M; Patel M; Gordon K
Immunotherapy; 2024 Apr; 16(7):431-446. PubMed ID: 38506262
[TBL] [Abstract][Full Text] [Related]
17. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
[TBL] [Abstract][Full Text] [Related]
18. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
[TBL] [Abstract][Full Text] [Related]
19. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ritchlin CT; Coates LC; McInnes IB; Mease PJ; Merola JF; Tanaka Y; Asahina A; Gossec L; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Landewé RB
Ann Rheum Dis; 2023 Nov; 82(11):1404-1414. PubMed ID: 37696588
[TBL] [Abstract][Full Text] [Related]
20. Bimekizumab for the Treatment of Psoriasis.
Freitas E; Blauvelt A; Torres T
Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
